Shares of Auris Medical Holding AG (NASDAQ:EARS) fell 9% during mid-day trading on Wednesday . The stock traded as low as $3.66 and last traded at $3.66, with a volume of 55,669 shares. The stock had previously closed at $4.02.

Several research firms have issued reports on EARS. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday. Leerink Swann restated a “buy” rating and set a $12.00 price objective on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The company’s market cap is $125.30 million. The firm’s 50 day moving average price is $3.82 and its 200 day moving average price is $4.11.

Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. During the same quarter in the previous year, the firm posted ($0.28) EPS. On average, equities research analysts forecast that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.